Andrx 'Cautiously Optimistic' It Will Pass FDA Facility Review

Drug Industry Daily
KEYWORDS FDA / GMP
A A

Andrx plans to meet with the FDA in November to discuss manufacturing issues that prompted the FDA to place the company's drug applications on hold.

To View This Article:

Login

Subscribe To Drug Industry Daily